Literature DB >> 2736754

Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects.

L B Mitchell1, D G Wyse, A M Gillis, H J Duff.   

Abstract

The time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone were determined with serial electrophysiologic studies in 34 patients with inducible ventricular tachycardia. A standardized oral loading dosage was used for all patients (1,200 mg/day for 14 days; 800 mg/day for 7 days; and 400 mg/day thereafter). Eleven patients had the studies performed at baseline and after 2, 6, 10, and 20 weeks. Subsequently, 23 patients had studies at baseline and after 2 and 10 weeks. Changes in atrial, sinus, and atrioventricular nodal properties and in conduction intervals were maximal within 2 weeks (early effects). For example, atrioventricular nodal Wenckebach cycle length increased between baseline (369 +/- 80 msec) and 2 weeks (498 +/- 78 msec) (p less than 0.001) but did not change further after 10 weeks (500 +/- 89 msec). However, ventricular Class III effects required 10 weeks to become maximal (late effects). For example, the QT interval during atrial pacing increased between baseline (355 +/- 36 msec) and 2 weeks (406 +/- 37 msec) (p less than 0.001) and increased further after 10 weeks (436 +/- 45 msec) (p less than 0.001). Antiarrhythmic effects also followed different time courses of onset. Suppression of ventricular premature beats was maximal within 2 weeks. However, suppression of ventricular tachycardia inducibility and slowing of ventricular tachycardia rate was not maximal for 10 weeks. Correlations between serum desethylamiodarone concentrations and some late effects suggest that the mechanism of the time delay to maximal ventricular Class III effects may involve desethylamiodarone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736754     DOI: 10.1161/01.cir.80.1.34

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable?

Authors:  Emmanuel M Kanoupakis; George E Kochiadakis; Emmanuel G Manios; Nikolaos E Igoumenidis; Hercules E Mavrakis; Panos E Vardas
Journal:  J Interv Card Electrophysiol       Date:  2003-02       Impact factor: 1.900

2.  Amiodarone therapy of intractable atrial flutter in a premature hydropic neonate.

Authors:  Z M Hijazi; L E Rosenfeld; J A Copel; C S Kleinman
Journal:  Pediatr Cardiol       Date:  1992-10       Impact factor: 1.655

3.  An atypical case of Brugada syndrome.

Authors:  Almpanis Georgios; Servos Georgios; Tragotsalou Nikolitsa; Koutsogiannou Persefoni; Mazarakis Andreas
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-10       Impact factor: 1.468

4.  To add amiodarone or not: that is the question.

Authors:  Matthew Jason Zimmerman; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

Review 5.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 6.  Approach to Management of Premature Ventricular Contractions.

Authors:  Michael P O'Quinn; Anthony J Mazzella; Prabhat Kumar
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-05

Review 7.  The diagnosis and management of ventricular arrhythmias.

Authors:  Kurt C Roberts-Thomson; Dennis H Lau; Prashanthan Sanders
Journal:  Nat Rev Cardiol       Date:  2011-02-22       Impact factor: 32.419

Review 8.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 9.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 10.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.